Abbott to acquire vascular disease specialists for $890M

Abbott has entered into a definitive agreement to acquire Cardiovascular Systems Inc. (CSI), a Minnesota-based healthcare technology company focused on treating peripheral artery disease (PAD) and coronary artery disease (CAD). The deal is worth approximately $890 million, and CSI’s stock price was up significantly after the announcement.

The acquisition will clearly help Abbott expand its cardiovascular portfolio. CSI is known for its atherectomy devices, including the Diamondback 360 Coronary Orbital Atherectomy System for treating CAD and Diamondback 360 Peripheral Orbital Atherectomy System for treating PAD.

“The acquisition of CSI will add new, complementary technologies to Abbott's leading vascular device offerings,” Lisa Earnhardt, Abbott’s executive vice president of medical devices, said in a prepared statement. “CSI has a talented and experienced team and a leading atherectomy system that will allow Abbott to provide physicians more tools to help patients live fuller lives.”

The CSI Diamondback 360 atherectomy system grinding through a calcified coronary lesion.

One of CSI's Diamondback 360 atherectomy devices grinding through a calcified coronary lesion. Image courtesy of CSI.

“We are pleased to have reached an agreement with a leading global company that shares our passion for the development and commercialization of innovative solutions for treating complex peripheral vascular disease and coronary artery disease,” added Scott Ward, CSI's chairman, president and chief executive officer. “We believe combining with Abbott delivers value to our patients, physician customers, employees and stockholders while continuing our work to save limbs and save lives every day.”

Once the deal has been finalized, CSI stockholders will receive $20 for each common share. The transaction has already been approved by both the Abbott Board of Directors and CSI Board of Directors.

In September 2021, Abbott acquired another vascular device company, Walk Vascular, though the financial details of that deal were not made public.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.